Ruminant BioTech
Ruminant BioTech is a New Zealand agri-tech company developing a slow-release bolus that delivers the methane inhibitor bromoform to cattle rumens, achieving over 70% methane reduction for 3+ months per application, targeting pasture-based dairy and beef farmers globally.
- Company typePrivate
- Founded2021
- HeadquartersPort Waikato, New Zealand
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Ruminant BioTech does
Ruminant BioTech is a New Zealand-based agri-tech company founded in 2021 that develops a slow-release oral bolus device designed to suppress enteric methane emissions from cattle. The core product is a single-application capsule administered to ruminants that resides in the animal's rumen and releases a sustained dose of bromoform (tribromomethane), a naturally occurring methane inhibitor, over approximately 100 days. Clinical trials have demonstrated sustained methane reductions of over 70% (with some results exceeding 90%) for more than three months per application, targeting the methanogen microbes responsible for roughly 95% of rumen methane output.
The bolus is differentiated by its delivery mechanism: unlike feed additives that require consistent dosing with every meal, the bolus is designed for pasture-based grazing systems where individual feed-dosing is impractical. The active ingredient is rapidly metabolised in the rumen, is not absorbed by the cow, and leaves no detectable residue in meat or dairy. The company holds patented technology for the slow-release bolus delivery system.
Ruminant BioTech is pre-commercial and plans to launch in New Zealand and Australia in 2026 following regulatory review under New Zealand's ACVM Act. Revenue will be generated through direct hardware sales of the bolus to dairy, sheep, and beef farmers operating pasture-based systems, with longer-term ambitions to expand across Brazil, Europe, the UK, USA, and Canada, targeting treatment of 100 million cows by 2035. The company is funded through a mix of venture capital (Regeneration.VC, NZGIF, AgriZeroNZ) and government grants from New Zealand, Australian, and Canadian government sources.
Ruminant BioTech firmographics
Firmographics- Name
- Ruminant BioTech
- Legal name
- Ruminant Biotech
- Website
- https://ruminantbiotech.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Ruminant BioTech is a New Zealand agri-tech company developing a slow-release bolus that delivers the methane inhibitor bromoform to cattle rumens, achieving over 70% methane reduction for 3+ months per application, targeting pasture-based dairy and beef farmers globally.
- Ownership category
- akta.pro rank
Ruminant BioTech industry classification
Industry- Product category
- Livestock methane mitigation (agri-tech animal health device)
- NAICS
- Animal Food Manufacturing (3111)
- SIC
- Agricultural Prod-Livestock & Animal Specialties (200)
- akta.pro primary industry
- Medicated & Functional Ruminant Feed (Ionophores, Buffers, Yeast/Probiotics, Mycotoxin Binders) (AFADAAAL)
- akta.pro secondary industry
- Rumen-Protected & Bypass Nutrients (Protected Fats, Methionine/Lysine) (AFADAAAK)
Keywords
Where Ruminant BioTech is headquartered
LocationHeadquarters
- HQ city
- Port Waikato
- HQ country
- New Zealand
- HQ region
- Oceania
Offices1 record
Markets served
Ruminant BioTech business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Operations, Personnel, Supply Chain, Marketing or Sales, Others
Revenue model
- Methane-Reducing Bolus Product: Pre-commercial stage. The company is developing a slow-release methane-inhibiting bolus for cattle that will be sold to farmers for application to their livestock. The bolus provides a 'set and forget' methane reduction solution practical for grass-fed/pasture-based farming operations.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels1 record
Ruminant BioTech product offering
Product offeringCore offering
Ruminant BioTech has developed a slow-release ruminal bolus that delivers the methane inhibitor bromoform (tribromomethane) directly to the rumen of cattle over approximately 90–100 days from a single oral application. The bolus has demonstrated sustained methane emissions reduction of over 70% (with earlier trials showing >90% knockdown) and is designed as a 'set and forget' solution tailored to pasture-based dairy, sheep, and beef farming systems. The product is currently pre-commercial and undergoing regulatory approval under New Zealand's ACVM Act ahead of a planned NZ and Australia launch in 2026.
Product overview
Ruminant BioTech offers a single core product: the methane-inhibiting bolus. This is a sustained-release capsule designed to reside in the rumen of cattle, delivering a naturally occurring methane inhibitor (bromoform/tribromomethane) over approximately three months. The bolus is designed specifically for pasture-grazed cattle systems and represents the company's sole commercial offering, targeting the reduction of enteric methane emissions from livestock. The company is currently in the regulatory approval phase with plans for commercial launch in New Zealand and Australia in 2026.
Differentiator
Problem solved
Functional benefit
Products and services
- Methane-Inhibiting Bolus Patented slow-release bolus administered orally to cattle that resides in the rumen and releases a sustained dose of bromoform (tribromomethane), a naturally occurring methane inhibitor, for approximately 90–100 days per single application. Demonstrated over 70% (and in earlier trials over 90%) methane knockdown sustained for 3+ months, designed as a 'set and forget' solution for dairy, sheep, and beef farmers operating pasture-based systems with no detectable residue in meat or dairy.
Quantifiable outcome
- Over 90% methane knockdown demonstrated in trials; sustained methane knockdown for over 3 months
- +3 more outcomes
Companies that use Ruminant BioTech
Customer profileSegments2 records
Ideal customer profiles2 records
Ruminant BioTech technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Ruminant BioTech partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered core and supporting.
- Dairy NZcoreR&D partner collaborating on research and development of the methane-inhibiting bolus technology for dairy cattle.
- University of WaikatocoreAcademic R&D partner providing research expertise and collaboration for the methane mitigation technology development.
- Ag ResearchcoreR&D partner specializing in agricultural research supporting the development and testing of the methane-reducing bolus.
- ESP MedicalsupportingMedical research partner contributing expertise to the R&D programme.
- CognoscosupportingResearch partner providing analytical and research capabilities for product development.
- EpiVetssupportingVeterinary epidemiology partner supporting research and data analysis.
- Analytica LaboratoriessupportingLaboratory partner providing analytical testing services for the R&D programme.
- FonterracoreMajor dairy co-operative and industry collaborator providing industry expertise and potential market access for the methane reduction solution.
- Beef+Lamb NZcoreIndustry body representing sheep and beef farmers, collaborating on product development and market introduction.
- GrasslandssupportingIndustry collaborator supporting the development and adoption of methane reduction solutions in grassland farming systems.
Scale indicators8 records
Recent moves6 records
Expansion highlights6 records
Ruminant BioTech competitors and assessment
Company assessmentDirect peers
- CH4 Global: CH4 Global develops Asparagopsis seaweed-based feed supplements to reduce enteric methane from cattle. It competes directly with Ruminant BioTech in the methane-mitigation-for-livestock category, though using a feed-additive rather than bolus delivery mechanism, making it a clear direct peer addressing the same problem from a different angle.
- Mootral: Mootral produces a feed-additive product combining garlic and citrus extracts to reduce enteric methane in cattle. It is a direct peer competing for the same dairy and beef farmer customers, though delivering methane reduction through daily feed inclusion rather than a long-acting bolus.
- Symbrosia: Symbrosia is a US-based startup commercializing Asparagopsis seaweed-based feed supplements for livestock methane reduction. It competes in the same agricultural methane-mitigation category with a different delivery mechanism, making it a direct peer targeting overlapping customer segments.
- Volta Greentech: Volta Greentech produces seaweed-based cattle feed supplements (Aimilox) targeting enteric methane reduction. As another seaweed-feed-additive competitor addressing the same problem, it is a direct peer in the methane-mitigation category for ruminants.
Broad incumbents
- Elanco Animal Health: Elanco commercializes Bovaer (3-NOP), a direct methane-inhibiting feed additive developed with DSM-firmenich and approved in multiple major dairy markets. As a large incumbent animal-health company with global distribution, it is the most established competitive threat to Ruminant BioTech's commercial ambitions.
- dsm-firmenich: dsm-firmenich co-developed the 3-NOP active ingredient behind Bovaer with Elanco and is a global leader in animal nutrition and health. It represents a deep-pocketed incumbent competing in the same methane-reduction category with a different delivery format.
- Zoetis: Zoetis is the largest global animal-health company and has publicly explored enteric-methane reduction opportunities. As a broad incumbent with established veterinary distribution and R&D infrastructure, it represents a potential acquirer or competitor with the resources to enter the methane-mitigation space at scale.
- Alltech: Alltech is a global animal nutrition company that has invested in methane-reduction research programs and feed-additive solutions. As an established broad incumbent in ruminant nutrition, it competes for the same farmer customer base and has the scale to influence market direction.
- Cargill: Cargill is a global agribusiness and animal nutrition major that has invested in methane-mitigation solutions and sustainability programs for livestock supply chains. Its scale, supply-chain reach, and processor relationships make it a broad incumbent peer that could either partner with or compete against Ruminant BioTech in major markets.
Emerging players
- ArkeaBio: ArkeaBio is developing a methane-reducing vaccine for cattle, representing an alternative mechanism (immunological) for enteric methane mitigation. As an early-stage company pursuing a different route to the same outcome, it is a relevant emerging peer with potential to disrupt the broader category.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Ruminant BioTech social profiles
Digital presenceRuminant BioTech financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ruminant BioTech leadership team
Management profileNumber of profiles
Profiles18 records
Ruminant BioTech funding detail
Funding detailFunding overview
Funding rounds5 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ruminant BioTech M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ruminant BioTech
What does Ruminant BioTech do?
Ruminant BioTech has developed a slow-release ruminal bolus that delivers the methane inhibitor bromoform (tribromomethane) directly to the rumen of cattle over approximately 90–100 days from a single oral application. The bolus has demonstrated sustained methane emissions reduction of over 70% (with earlier trials showing >90% knockdown) and is designed as a 'set and forget' solution tailored to pasture-based dairy, sheep, and beef farming systems. The product is currently pre-commercial and undergoing regulatory approval under New Zealand's ACVM Act ahead of a planned NZ and Australia launch in 2026.
Is Ruminant BioTech a public or private company?
Ruminant BioTech is a private company. It is classified as venture growth investor backed and is currently operating.
When was Ruminant BioTech founded?
Ruminant BioTech was founded in 2021. It employs 11 to 50 people.
Where is Ruminant BioTech based?
Ruminant BioTech is headquartered in Port Waikato, New Zealand, in the Oceania region.
How does Ruminant BioTech make money?
One revenue line is on record: methane-Reducing Bolus Product.
Who are Ruminant BioTech's main competitors?
Direct peers on record are CH4 Global, Mootral, Symbrosia and Volta Greentech. Broad incumbents are Elanco Animal Health, dsm-firmenich, Zoetis, Alltech and Cargill. ArkeaBio is listed as an emerging player.
Does Ruminant BioTech have an API?
No public API is recorded for Ruminant BioTech.
What industry is Ruminant BioTech in?
Ruminant BioTech's product category is Livestock methane mitigation (agri-tech animal health device). Its primary akta.pro industry code is AFADAAAL, Medicated & Functional Ruminant Feed (Ionophores, Buffers, Yeast/Probiotics, Mycotoxin Binders), with a secondary code of AFADAAAK, Rumen-Protected & Bypass Nutrients (Protected Fats, Methionine/Lysine). Its NAICS code is 3111 and its SIC code is 200.